AORT: Bullish Pennant detected on 6 Aug 2026

AORT is forming a bullish pennant after the stock opened at $27.54 on Tuesday, with the pattern currently trading at $26.17 between support at $22.83 and resistance at $28.29. The pattern scores are strong across the board: structure (15.0/15), volume (12.0/12), and breakout (13.0/13) combine for an overall quality score of 83.0/98 with a 61.34% historical win probability. Volume shows robust 1.72x average daily activity, supporting the consolidation structure. The pennant sits 36.59% above the 52-week low but remains 45.76% below the 52-week high, indicating recovery potential within a defined range.

Artivion announced that second quarter 2026 financial results will be released on Thursday, August 6, 2026, after the market closes—coinciding exactly with this analysis date. This earnings trigger creates immediate fundamental uncertainty and explains the consolidation. Analysts expect the company to post earnings of $0.0088 per share and revenue of $120.0170 million for the quarter. Earlier, Q1 2026 achieved revenue of $116.3 million versus $99.0 million in Q1 2025, an increase of 18% on a GAAP basis and 12% on a non-GAAP constant currency basis. Management will present at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 9:30 a.m. ET at the InterContinental Boston Hotel, providing near-term visibility catalysts.

A successful breakout above $28.29 resistance targets the conservative measure of $28.12 (minimal upside room suggesting near-term consolidation), with validated strength requiring volume confirmation above the recent 1.72x relative volume threshold. The invalidation level sits at $22.83 support; a breakdown below this price kills the bullish pennant setup. The 61.34% win probability reflects historical pennant efficacy, though breakout direction remains uncertain given today's earnings release timing. RSI at 55.09 suggests neutral momentum—neither overbought nor oversold—providing no confirmation bias ahead of results.

Artivion is expected to announce its Q2 2026 results after the market closes on Thursday, August 6th, introducing severe headline risk to this technical setup within hours. Earnings beats or misses could violently override pattern mechanics. The stock shows a three-month decline of -27.12%, indicating accumulated selling pressure despite recent two-week gains of 4.1%. The 52-week trading range (low $19.16, high $48.25) reveals extreme volatility around fundamentals. Beta of 0.66 provides some cushion versus broader market drawdowns, but the medical device sector regime scores only 0.58 bullish strength, lagging the broader 0.93 bullish market regime—a disconnect suggesting sector-specific headwinds.

We scan more than 6,000 NYSE and NASDAQ stocks every trading day and compare each detected pattern against a database of 370,000+ historical detections. Every setup is scored across three dimensions: Structure, Volume, and Breakout Readiness. Win probability is a calibrated estimate of how similar historical setups performed over the following 10 trading days. This is a swing trading tool built for multi-day holds. It is not built or tested for day trading.